title: [Combined Therapy with Targeted Drugs in Lung Cancer].
abstract: As targeted therapies for lung cancer, EGFR tyrosine kinase inhibitors(EGFR-TKIs)and ALK-TKIs have been approved for EGFR mutation-positive advanced non-small cell lung cancer(NSCLC)and ALK-fusion gene-positive advanced NSCLC, respectively. Very recently, an anti-immune checkpoint antibody was approved for advanced or recurrent NSCLC. In this article, the current status of combined therapy is reviewed with a focus on EGFR-TKIs, which are the most frequently used targeted therapies in clinical practice for lung cancer. To increase the efficacy of EGFR-TKIs in EGFR-mutant NSCLC, a large number of clinical trials using EGFR-TKIs and other agents, such as cytotoxic chemotherapy, angiogenesis inhibitors, or antiimmune checkpoint antibodies, are being conducted. On the other hand, several trials have also been conducted to examine the efficacy of EGFR-TKIs in adjuvant settings for earlier staged EGFR-mutant NSCLC. Based on the results of these trials, a paradigm shift concerning treatment with targeted therapy for EGFR-mutant NSCLC is possible in the future.
authors.affiliation: Dept. of Medical Oncology, Cancer Research Institute, Kanazawa University.
authors.forename: Seiji
authors.initials: S
authors.lastname: Yano
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D016923:Cell Death / Q000187:drug effects; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D058990:Molecular Targeted Therapy